SBV Journal of Basic, Clinical and Applied Health Science

Register      Login

VOLUME 5 , ISSUE 2 ( April-June, 2022 ) > List of Articles


Mucormycosis in Post-COVID Patients: A Review

JV Sabarianandh, Packia Sakaya Mercy, K Manimekalai, L Bernaitis, L Benita Mary

Keywords : COVID-19, COVID-19-associated mucormycosis (CAM), Mucormycosis

Citation Information : Sabarianandh J, Mercy PS, Manimekalai K, Bernaitis L, Mary LB. Mucormycosis in Post-COVID Patients: A Review. 2022; 5 (2):34-38.

DOI: 10.5005/jp-journals-10082-03143

License: CC BY-NC 4.0

Published Online: 25-05-2022

Copyright Statement:  Copyright © 2022; The Author(s).


The mucormycetes fungus causes mucormycosis (also known as zygomycosis), a dangerous but uncommon fungal infection. Molds can be found in a variety of places. Mucormycosis is a fungus that primarily affects those who have health problems or who use medications that lower the body's ability to fight infections and sickness. It is a dangerous invasive fungal infection that can impact people who have uncontrolled diabetes, kidney failure, organ transplants, long-term steroid and immunosuppressive medicines, cirrhosis, burns, AIDS, and tumors such as lymphomas and leukemias. The researchers conducted a systematic review of a number of studies that demonstrated the presence of mucormycosis in post-COVID patients. The researchers began to observe how mucormycosis affected those who had been infected with a virus. We found nine articles on Google Scholar and the Internet using the keywords “COVID” and “mucormycosis,” describing 13 post-COVID patients infected with mucormycosis. Mucormycosis can appear in at least six different clinical syndromes, including rhino-orbito-cerebral, lung, cutaneous, gastrointestinal, disseminated, and other: pulmonary disease (three study papers with four trials each and one research report with four patients); gastrointestinal disease (one research paper with one case); and disseminated disease (one research paper with one case). Seven of the 13 patients died, according to previous study reports. According to Worldometer, coronavirus disease-2019 (COVID-19) has been reported in almost 88 million cases, with nearly 1.9 million deaths globally. Despite the fact that there are no signs of mucormycosis in COVID patients, the death rate is over 50%. The situation is really alarming. Because delayed diagnosis and inadequate treatment can lead to poor outcomes, more research is needed.

  1. Bouza E, Munoz P, Guinea J. Mucormycosis: an emerging disease? Eur Soc Clin Microbiol Infect Dis 2006;12(7):7–23. DOI: 10.1111/j.1469-0691.2006.01604.x.
  2. Binder U, Maurer E, Lass-Florl C. Mucormycosis–from the pathogens to the disease. Clin Microbiol Infect 2014;20(6):60–66. DOI: 10.1111/1469-0691.12566.
  3. Branscomb R. An overview of mucormycosis. Lab Med 2002;33(6): 453–455. DOI: 10.1309/ML2Q-9JWN-KRR7-366T.
  4. Pan American Health Organization. Epidemiological alert: COVID-19 associated Mucormycosis. World Health Organization; 2021. p. 1–6.
  5. Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018;56(Suppl 1):93–101. DOI: 10.1093/mmy/myx101.
  6. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Am Soc Microbiol 2005;18(3):556–569. DOI: 10.1128/CMR.18.3.556-569.2005.
  7. Suganya R, Malathi N, Karthikeyan V, Janagaraj VD. Mucormycosis: a brief review. J Pure Appl Microbiol 2019;13(1):161–165. DOI: 10.22207/JPAM.13.1.16.
  8. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land, a tale of two pathogens. Indian J Ophthalmol 2021;69(2): 244–252. DOI: 10.4103/ijo.IJO_3774_20.
  9. Prithiv Kumar KR. Mucormycosis: A black fungus–post covid complications. J Regen Biol Med 2021;3(4):1–8. DOI: 10.37191/Mapsci-2582-385X-3(4)-078.
  10. Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehraparvar G, et al. Mucormycosis in patients with COVID-19: a cross-sectional descriptive multicentre study from Iran. Mycoses 2021;64(10): 1238–1252. DOI: 10.1111/myc.13334.
  11. Morusupalli RV, Chennamchetty VK, Adimulapu S, Kola BP, De Padua M, Ambika C, et al. Post-COVID pulmonary mucormycosis– a case report, IP Indian J Immunol Respir Med 2021;6(1):62–66. DOI: 10.18231/j.ijirm.2021.014.
  12. Camara-Lemarroy CR, González-Moreno EI, Rodríguez-Gutiérrez R, Rendón-Ramírez EJ, Ayala-Cortés AS, Fraga-Hernández ML, et al. Clinical features and outcome of mucormycosis. Interdiscip Perspect Infect Dis 2014;2014:562610. DOI: 10.1155/2014/562610.
  13. Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol 2021;69(4):1002–1004. DOI: 10.4103/ijo.IJO_3763_20.
  14. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021;186(2):289–298. DOI: 10.1007/s11046-021- 00528-2.
  15. Pilmis B, Lanternier F, Lortholary O. Mucormycosis: therapeutic news. Med Sci (Paris) 2013;1:25–30. DOI: 10.1051/medsci/201329s106.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.